Review article · 2024 · Open access

Function and therapeutic prospects of next-generation probiotic Akkermansia muciniphila in infectious diseases

Lifeng Li, Mingchao Li, Yihua Chen, Zengyuan Yu, Ping Chen, Zhidan Yu, Weyland Cheng, Wancun Zhang, Zhaobao Wang, Xueyan Gao, Huiqing Sun, Xiaolei Wang

Frontiers in Microbiology, 15, 1354447 · Published 6 February 2024 · DOI 10.3389/fmicb.2024.1354447

Open PDFView at the publisherCite this paper

In brief

“Function and therapeutic prospects of next-generation probiotic Akkermansia muciniphila in infectious diseases” is a 2024 review article by Lifeng Li and 11 co-authors, published in Frontiers in Microbiology. OpenAlex counts 49 citations as of 21 November 2026, which puts it in the top 1% of works published in 2024 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Microbiology.

Citations
49
Most cited in
2026 (22)
Field-weighted impact
1.41
References
83
Authors
12

Abstract

Akkermansia muciniphila is a gram-negative bacterium that colonizes the human gut, making up 3–5% of the human microbiome. A. muciniphila is a promising next-generation probiotic with clinical application prospects. Emerging studies have reported various beneficial effects of A. muciniphila including anti-cancer, delaying aging, reducing inflammation, improving immune function, regulating nervous system function, whereas knowledge on its roles and mechanism in infectious disease is currently unclear. In this review, we summarized the basic characteristics, genome and phenotype diversity, the influence of A. muciniphila and its derived components on infectious diseases, such as sepsis, virus infection, enteric infection, periodontitis and foodborne pathogen induced infections. We also provided updates on mechanisms how A. muciniphila protects intestinal barrier integrity and modulate host immune response. In summary, we believe that A. muciniphila is a promising therapeutic probiotic that may be applied for the treatment of a variety of infectious diseases.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Li, L., Li, M., Chen, Y., Yu, Z., Chen, P., Yu, Z., Cheng, W., Zhang, W., Wang, Z., Gao, X., Sun, H., & Wang, X. (2024). Function and therapeutic prospects of next-generation probiotic Akkermansia muciniphila in infectious diseases. Frontiers in Microbiology, 15, 1354447. https://doi.org/10.3389/fmicb.2024.1354447

MLA 9

Li, Lifeng, et al. “Function and therapeutic prospects of next-generation probiotic Akkermansia muciniphila in infectious diseases.” Frontiers in Microbiology, vol. 15, 2024, p. 1354447. https://doi.org/10.3389/fmicb.2024.1354447.

Chicago

Li, Lifeng, Mingchao Li, Yihua Chen, Zengyuan Yu, Ping Chen, Zhidan Yu, Weyland Cheng, et al. 2024. “Function and therapeutic prospects of next-generation probiotic Akkermansia muciniphila in infectious diseases.” Frontiers in Microbiology 15: 1354447. https://doi.org/10.3389/fmicb.2024.1354447.

Harvard

Li, L. et al. (2024) ‘Function and therapeutic prospects of next-generation probiotic Akkermansia muciniphila in infectious diseases’, Frontiers in Microbiology, 15, p. 1354447. doi:10.3389/fmicb.2024.1354447.

IEEE

L. Li et al., “Function and therapeutic prospects of next-generation probiotic Akkermansia muciniphila in infectious diseases,” Frontiers in Microbiology, vol. 15, p. 1354447, 2024, doi: 10.3389/fmicb.2024.1354447.

BibTeX

@article{li2024function,
  title     = {{Function and therapeutic prospects of next-generation probiotic Akkermansia muciniphila in infectious diseases}},
  author    = {Li, Lifeng and Li, Mingchao and Chen, Yihua and Yu, Zengyuan and Chen, Ping and Yu, Zhidan and Cheng, Weyland and Zhang, Wancun and Wang, Zhaobao and Gao, Xueyan and Sun, Huiqing and Wang, Xiaolei},
  journal   = {Frontiers in Microbiology},
  year      = {2024},
  volume    = {15},
  pages     = {1354447},
  doi       = {10.3389/fmicb.2024.1354447},
  url       = {https://doi.org/10.3389/fmicb.2024.1354447}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202499
20251818
20262222

Its field-weighted citation impact is 1.41: it has been cited 1.41 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods

  • Akkermansia muciniphila
  • probiotics
  • infectious diseases
  • sepsis
  • viral infection
  • gastrointestinal infections
  • periodontitis
  • foodborne pathogens

Work with this paper

Most-cited papers in Agricultural and Biological Sciences

All highly cited Agricultural and Biological Sciences papers

Questions about this paper

How do I cite this paper in APA style?

Li, L., Li, M., Chen, Y., Yu, Z., Chen, P., Yu, Z., Cheng, W., Zhang, W., Wang, Z., Gao, X., Sun, H., & Wang, X. (2024). Function and therapeutic prospects of next-generation probiotic Akkermansia muciniphila in infectious diseases. Frontiers in Microbiology, 15, 1354447. https://doi.org/10.3389/fmicb.2024.1354447

How many times has this paper been cited?

49 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Microbiology: sign in and open the PDF from this page.

Who wrote this paper?

Lifeng Li, Mingchao Li, Yihua Chen, Zengyuan Yu, Ping Chen, Zhidan Yu, Weyland Cheng, Wancun Zhang, Zhaobao Wang, Xueyan Gao, Huiqing Sun, Xiaolei Wang.

What is the DOI of this paper?

10.3389/fmicb.2024.1354447, permanently at https://doi.org/10.3389/fmicb.2024.1354447. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.